Context Therapeutics (CNTX) Accounts Payables (2020 - 2026)

Context Therapeutics has disclosed Accounts Payables across 7 years of filings, most recently posting $2.5 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $2.5 million, up 146.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (up 146.26% YoY), and the FY2025 annual result was $2.5 million, up 74.42% from the prior year.
• Accounts Payables came in at $2.5 million for Q1 2026 at Context Therapeutics, down from $2.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $2.7 million in Q3 2025 to a low of $454834.0 in Q1 2022.
• The 5-year median for Accounts Payables is $1.5 million (2024), against an average of $1.6 million.
• Across the five-year window, Accounts Payables plunged 51.52% in 2022 and jumped 291.8% in 2025, its largest moves.
• Context Therapeutics' Accounts Payables stood at $936330.0 in 2022, then jumped by 154.51% to $2.4 million in 2023, then sank by 39.06% to $1.5 million in 2024, then jumped by 74.42% to $2.5 million in 2025, then retreated by 2.65% to $2.5 million in 2026.
• The last three Accounts Payables figures came in at $2.5 million (Q1 2026), $2.5 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.